Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Section of Clinical Microbiology, Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, Utah, USA.
Clin Infect Dis. 2020 Dec 17;71(10):2744-2751. doi: 10.1093/cid/ciaa508.
The clinical signs and symptoms of acute respiratory tract infections (RTIs) are not pathogen specific. Highly sensitive and specific nucleic acid amplification tests have become the diagnostic reference standard for viruses, and translation of bacterial assays from basic research to routine clinical practice represents an exciting advance in respiratory medicine. Most recently, molecular diagnostics have played an essential role in the global health response to the novel coronavirus pandemic. How best to use newer molecular tests for RTI in combination with clinical judgment and traditional methods can be bewildering given the plethora of available assays and rapidly evolving technologies. Here, we summarize the current state of the art with respect to the diagnosis of viral and bacterial RTIs, provide a practical framework for diagnostic decision making using selected patient-centered vignettes, and make recommendations for future studies to advance the field.
急性呼吸道感染(RTI)的临床症状和体征没有病原体特异性。高灵敏度和特异性的核酸扩增检测已成为病毒诊断的参考标准,将细菌检测从基础研究转化为常规临床实践是呼吸医学的一个令人兴奋的进展。最近,分子诊断在全球应对新型冠状病毒大流行的过程中发挥了重要作用。鉴于目前有大量的检测方法和快速发展的技术,如何最好地将新型分子检测与临床判断和传统方法结合使用,可能会令人困惑。在这里,我们总结了目前在病毒性和细菌性 RTI 诊断方面的最新技术,通过选择以患者为中心的病例提供了一个实用的诊断决策框架,并为推进该领域的未来研究提出了建议。